$4.38
+0.07(1.74%)
Mkt Cap $1.1B
$1.13
$5.91
52-Week Range
At a Glance
AI-generatedTaysha Gene Therapies, Inc.
8-K
Taysha Gene Therapies reported full-year 2025 financial results with research and development expenses of $86.4 million, general and administrative expenses of $33.9 million, and net loss of $109.0 million ($0.34 per share), alongside $319.8 million in cash and cash equivalents as of December 31, 2025. The company provided updates on TSHA-102 program progress, including dosing in REVEAL pivotal and ASPIRE trials on track for Q2 2026 completion and FDA alignments on BLA requirements.$1.1B
Market Cap
$7M
Revenue
-$74M
Net Income
Employees73
Fundamentals
How The Business Makes Money
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001806310
ISINUS8776191061
CUSIP877619106
Phone214 612 0000
Address3000 Pegasus Park Drive, Dallas, TX, 75247, US
SEC EDGAR